These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 3644022)

  • 1. Inhibitors of cholesterol synthesis and cataracts.
    Cenedella RJ
    JAMA; 1987 Mar; 257(12):1602. PubMed ID: 3644022
    [No Abstract]   [Full Text] [Related]  

  • 2. Pravastatin--ocular side effects after a two year follow-up?
    Behrens-Baumann W; Thiery J; Fieseler HG; Seidel D
    Lens Eye Toxic Res; 1990; 7(3-4):311-8. PubMed ID: 2129219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Could cholesterol-lowering drugs cause cataracts?
    Harv Mens Health Watch; 2014 Jan; 18(6):8. PubMed ID: 24683611
    [No Abstract]   [Full Text] [Related]  

  • 4. Is your cholesterol drug putting you at risk for vision loss?
    Harv Health Lett; 2013 Dec; 39(2):8. PubMed ID: 24634971
    [No Abstract]   [Full Text] [Related]  

  • 5. [Inhibition of cholesterol synthesis and cataract].
    Hockwin O; Kojima M; Czubayko F; von Bergmann K
    Fortschr Ophthalmol; 1991; 88(4):393-5. PubMed ID: 1786929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholesterol drugs: should you be taking one?
    Consum Rep; 1998 Oct; 63(10):54-5. PubMed ID: 10342966
    [No Abstract]   [Full Text] [Related]  

  • 7. [Pharmacologic therapy of arteriosclerosis. II. New directions].
    Santafé Oroz J; Segarra Domènech J
    Med Clin (Barc); 1985 Jan; 84(3):115-22. PubMed ID: 3919229
    [No Abstract]   [Full Text] [Related]  

  • 8. Regulation of the last two enzymatic reactions in cholesterol biosynthesis in rats: effects of BM 15.766, cholesterol, cholic acid, lovastatin, and their combinations.
    Honda A; Shefer S; Salen G; Xu G; Batta AK; Tint GS; Honda M; Chen TC; Holick MF
    Hepatology; 1996 Aug; 24(2):435-9. PubMed ID: 8690416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase.
    Amin D; Rutledge RZ; Needle SN; Galczenski HF; Neuenschwander K; Scotese AC; Maguire MP; Bush RC; Hele DJ; Bilder GE; Perrone MH
    J Pharmacol Exp Ther; 1997 May; 281(2):746-52. PubMed ID: 9152381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of small GTP-binding proteins in lovastatin-induced cataracts.
    Rao PV; Robison WG; Bettelheim F; Lin LR; Reddy VN; Zigler JS
    Invest Ophthalmol Vis Sci; 1997 Oct; 38(11):2313-21. PubMed ID: 9344354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of primary moderate hypercholesterolemia with lovastatin (mevinolin) and colestipol.
    Vega GL; Grundy SM
    JAMA; 1987 Jan; 257(1):33-8. PubMed ID: 3537351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro.
    Flint OP; Masters BA; Gregg RE; Durham SK
    Toxicol Appl Pharmacol; 1997 Jul; 145(1):91-8. PubMed ID: 9221828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of neuronal cholesterol biosynthesis with lovastatin leads to impaired synaptic vesicle release even in the presence of lipoproteins or geranylgeraniol.
    Mailman T; Hariharan M; Karten B
    J Neurochem; 2011 Dec; 119(5):1002-15. PubMed ID: 21899539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of simvastatin and cholestyramine in familial and nonfamilial hypercholesterolemia. Multicenter Group I.
    Stein E; Kreisberg R; Miller V; Mantell G; Washington L; Shapiro DR
    Arch Intern Med; 1990 Feb; 150(2):341-5. PubMed ID: 2405804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of drugs affecting cholesterol biosynthesis pathway on BM 15.766-induced 7-dehydrocholesterol accumulation in rats. An animal model for testing compounds reducing cholesterol synthesis.
    Pill J; Stegmeier K; Schmidt FH
    Methods Find Exp Clin Pharmacol; 1990 Apr; 12(3):167-74. PubMed ID: 2352446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperlipidemia following heart transplantation: natural history and intervention with mevinolin (lovastatin).
    Ballantyne CM; Jones PH; Payton-Ross C; Patsch W; Short HD; Noon GP; Gotto AM; DeBakey ME; Young JB
    Transplant Proc; 1987 Aug; 19(4 Suppl 5):60-2. PubMed ID: 3303569
    [No Abstract]   [Full Text] [Related]  

  • 17. [HMG-CoA-reductase inhibitors: a new principle in the treatment of hypercholesterolemia].
    Saxenhofer H; Weidmann P
    Ther Umsch; 1990 Jun; 47(6):509-13. PubMed ID: 2375007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparison of 2 cholesterol synthesis inhibitors (simvastatin and pravastatin)].
    Golay A; Lehmann T; James R; Pometta D
    Schweiz Med Wochenschr; 1993 Aug; 123(33):1553-8. PubMed ID: 8372340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HMG CoA reductase inhibitor-induced myotoxicity: pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture.
    Flint OP; Masters BA; Gregg RE; Durham SK
    Toxicol Appl Pharmacol; 1997 Jul; 145(1):99-110. PubMed ID: 9221829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Side effects of cholesterol synthesis inhibitors].
    Wolterbeek R; Stricker BH
    Ned Tijdschr Geneeskd; 1993 May; 137(19):973-7. PubMed ID: 8497334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.